Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526819 · ClinicalTrials.gov registry record · Phase 1
SMP-3124LP in Adults With Advanced Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Sumitomo Pharma America.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 10
- Study locations
NCT06526819: Recruiting Phase 1 study of Solid Tumor, sponsored by Sumitomo Pharma America.
NCT06526819 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Sumitomo Pharma America. The registered enrollment target is 120 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (46% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06526819, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Sumitomo Pharma America.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 10
- Study locations
Study Summary
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Conditions Studied
Interventions
- DRUG SMP3124LP
Study Locations (10)
Tennessee
- SCRI Oncology Partners - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Other
- National Cancer Center Hospital East - Kashiwa-shi
- Kyoto University Hospital - Kyoto
California
- Cedars Sinai Medical Center - Los Angeles
Colorado
- Sarah Cannon Research Institute at HealthOne - Denver
Illinois
- Northwestern Medicine Cancer Center - Chicago
Ohio
- Ohio State University - Columbus
Texas
- MD Anderson Cancer Center - Houston
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-08-14 |
| Est. Completion | 2029-05 |
| Phase | Phase 1 |
What NCT06526819 shows while recruiting
NCT06526819 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which SMP3124LP is the first listed.
NCT06526819 lists 10 locations in 8 states (Tennessee, Other, California).
Frequently Asked Questions
What is clinical trial NCT06526819 about?
NCT06526819 is a clinical study titled "SMP-3124LP in Adults With Advanced Solid Tumors". An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
What is the current status of trial NCT06526819?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-08-14. Estimated completion is 2029-05.
What conditions does trial NCT06526819 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06526819?
The interventions under investigation include: SMP3124LP (DRUG).
Who is sponsoring clinical trial NCT06526819?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06526819 being conducted?
This trial has 10 study locations across California, Colorado, Illinois, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06526819's enrollment target sits among peer trials
120 72nd of 196 higher than 122 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI